电邮这篇文章 Thiaside diuretics in combination with inhibitors of angiotensin-converting enzyme in patients with diabetes mellitus type 2 comorbid with arterial hypertension
- 作者: Chazova IE1, Mychka VВ1, Duishvili DE1
-
隶属关系:
- Российский кардиологический научно-производственный комплекс МЗ и СР РФ
- 期: 卷 79, 编号 8 (2004)
- 页面: 28-31
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/29879
- ID: 29879
如何引用文章
全文:
详细
Aim. To study the effect of corenitek monotherapy for 16 weeks on parameters of 24-h monitoring of
arterial pressure, carbohydrate, lipid, purin metabolism in patients with mild and moderate arterial
hypertension (AH) and diabetes mellitus (DM) type 2.
Material and methods. 20 patients with DM type 2, mild or moderate AH received co-renitek (1-2
tablets a day) for 16 weeks. Before the treatment and 16 weeks later the patients were examined (24h AH monitoring, carbohydrate, lipid, purin, electrolyte metabolism).
Results. Co-renitek treatment of DM type 2 patients with hypertension led to a significant lowering of
mean systolic and diastolic pressure, improvement of 24-h AP profde and reduction of fasting glucose
level. Co-renitek proved to be metabolically neutral in relation to lipid, purin and electrolyte metabolism.
Conclusion. Co-renitek is effective and safe antihypertensive drug for treatment of arterial hypertension in patients with diabetes mellitus type 2.
arterial pressure, carbohydrate, lipid, purin metabolism in patients with mild and moderate arterial
hypertension (AH) and diabetes mellitus (DM) type 2.
Material and methods. 20 patients with DM type 2, mild or moderate AH received co-renitek (1-2
tablets a day) for 16 weeks. Before the treatment and 16 weeks later the patients were examined (24h AH monitoring, carbohydrate, lipid, purin, electrolyte metabolism).
Results. Co-renitek treatment of DM type 2 patients with hypertension led to a significant lowering of
mean systolic and diastolic pressure, improvement of 24-h AP profde and reduction of fasting glucose
level. Co-renitek proved to be metabolically neutral in relation to lipid, purin and electrolyte metabolism.
Conclusion. Co-renitek is effective and safe antihypertensive drug for treatment of arterial hypertension in patients with diabetes mellitus type 2.
作者简介
I Chazova
Российский кардиологический научно-производственный комплекс МЗ и СР РФРоссийский кардиологический научно-производственный комплекс МЗ и СР РФ
V Mychka
Российский кардиологический научно-производственный комплекс МЗ и СР РФРоссийский кардиологический научно-производственный комплекс МЗ и СР РФ
D Duishvili
Российский кардиологический научно-производственный комплекс МЗ и СР РФРоссийский кардиологический научно-производственный комплекс МЗ и СР РФ
参考
- Hansson L. The Hypertension Optimal Treatment study (the HOT Study). Blood Press. 1999; 2: 62-68.
- Schrier R. W., Estacio R. 0. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension.N. Engl. J. Med. 2000; 343: 1969-1974.
- Lender D., Arauz-Pacheco C, Breen L. et al. A double blind comparison of the effect of amlodipin and enalapril on insulin sensitivity in hypertensive patients. Am. J. Hypertens. 1999; 12: 298-303.
- Bossaller C, Auch-Schwelk W., Grafe M. Effects of converting enzyme inhibition on endothelial bradykinin metabolism and endothelial-dependent vascular relaxation. Agents and Actions 1992; 38: 171-177.
- Fogari R., Preti P., Banderali A. et al. ACE-inhibition but not angiotensin II antagonism improves fibrinolysis and sensitivity in hypertensive post-menopausal women. J. Hypertens. 1999; 17 (suppl. 3): S143.
- Ruggcnenti P., Pcarna A., Gherardi G. et al. Properties of ACE-nhibition in nondiabetic nephropathies with nonnephronic proteinuria. Lancet 1999; 354: 359-364.
- Hansson L., Lindholm L., Niskanen L. et al. Effects of ACE in hibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: CAPP randomized trial. Lancet 1999; 353: 611-616.
- Gerstein H. C, Bosch J., Pogue J. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an АСЕ inhibitor and vitamin E in highrisk patients with diabetes. The MICRO-HOPE study. Diabetes Care 1996; 19: 1225-1228.
- Houston M. C. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am.Heart J. 1988; 115 (3): 640-656.
- Bauer J. H., Brooks C. S., Weidmann I. et al. Effects of diuretic and propranolol on plasma lipoprotein lipids. Clin. Pharmacol. Ther. 1981; 30: 35-43.
- Gluck Z., Weidmann P., Mordasini R. Increased serum lowdensity lipoprotein cholesterol in men, treated short-term with the diuretic chlorthalidone. Metabolism 1980; 29: 240-245.
- Johnson B. F. The emerging problem of plasma lipid changes during antihypertensive therapy. J. Cardiovasc. Pharmacol. 1982; 4 (suppl. 2): S213-S221.
- Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артер. гипертенз. 2001; 7 (1, прил.): 1-16.
- Ames R. P. Negative effects of diuretic drugs on metabolic risk factors of coronary heart disease: possible alternative drug therapies. Am. J. Cardiol. 1983; 51: 632-638.
- Чазова И. E., Мычка В. Б., Стукалова О. В., Синицин В. Е. Роль ингибиторов АПФ в лечении сахарного диабета типа 2: фокус на аккупро. Артер. гипертенз. 2003; 6: 209-211.
- Мычка В. Б., Масенко В. Б., Творогова М. Г. и др. Применение периндоприла у больных мягкой и умеренной артериальной гипертензией и метаболическим синдромом. Артер. гипертенз. 2002; 1: 178-181.
- Беленков Ю. Н., Чазова И. Е., Мычка В. Б. и др. Многоцентровое рандомизированное открытое исследование по изучению эффективности изменения образа жизни и терапии ингибиторами АПФ (квинаприлом) у больных ожирением и артериальной гипертензией (ЭКО). Артер. гипертенз. 2003; 9: 196-199.
- Giverts M. M. Manipulation of the renin-angiotensin system. Circulation 2001; 104 (5): 14-18.
- Griendling K. K., Minieri С A., Ollerenshow J. D. et al. Angiotensin II stimulates NADH and NADH oxydase activity in cultured vascular smooth muscle cells. Circ. Res. 1994; 74 (6): 1141-1148.
补充文件
